ArticleTechnical innovations & patient support in radiation oncology2026
Patient-reported outcome and prognostic factors for survival in patients with metastases in soft tissue treated with palliative radiotherapy.
Article in Technical innovations & patient support in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To determine the overall result of treatment with palliative radiotherapy for patients with soft tissue metastases and to identify prognostic factors for overall survival. Methods and materials: From September 2015 until April 2023, 120 patients were included. Treatment outcome was reported via telephone consultations at four and eight weeks after the last fraction. Patients who reported benefit were classified as responders, while those without benefit were classified as non-responders. Results: The most frequent complaints were pain (n = 104), swelling (n = 20) or functional disability (n = 19). There was a decrease or disappearance in 61% of complaints 8 weeks after last fraction of treatment. Median overall survival was 4.3 months (95% CI 2.4-9.3). 26 patients (22%, 95% CI 14%-29%) died within 2 months. From the 94 patients alive two months after treatment 66 responders had a significant better survival compared to 25 non-responders (6.6 vs 3.8 months, p = 0.005).Multivariable analysis identified 5 prognostic factors for overall survival: PTV-volume, time from diagnosis to treatment, total number of metastases, systemic treatment options after radiotherapy, and number of organs. Conclusion: Palliative radiotherapy for patients with soft tissue metastases provided benefit in 61% of complaints that were the reason for treatment. Responders had a significantly better survival than non-responders. Although 5 prognostic factors for survival were identified, further research is needed to identify patients who benefit from palliative radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.